高级检索

Src激酶家族与紫杉醇耐药相关性的研究进展

Advances of Src kinase family and paclitaxel resistance

  • 摘要: Src激酶家族(SFK)在许多恶性肿瘤中均有高表达,对于肿瘤细胞的恶性行为具有广泛的调节作用。紫杉醇是临床上广泛应用的化疗药物,但由于耐药性的出现使其疗效逐渐下降。本文就SFK的结构与调节方式、紫杉醇耐药产生的分子机制以及SFK调节紫杉醇耐药的研究进展进行综述,以期为基于紫杉醇的肿瘤治疗方案提供新的治疗参考依据。

     

    Abstract: Src family kinase(SFK)highly expresses in many types of cancers, broadly adjusting their malignant behaviors. Paclitaxel is a widely used chemical agent. However, because of constant resistance, the effect of paclitaxel has been greatly attenuated. The present review summaries the recent research progress of the structure and adjustment of SFK and the molecular mechanism of paclitaxel resistance, as well as the regulation of SFK on paclitaxel resistance, in order to provide new references and evidences upon the paclitaxel-based tumor therapy.

     

/

返回文章
返回